The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

详细信息    查看全文

• 作者：Bartley P. Griffith ; MD^a ; ^{BGRIFFITH@smail.umaryland.edu} ; Mark B. Anderson ; MD^b ; Louis E. Samuels ; MD^c ; Walter E. Pae Jr. ; MD^d ; Yoshifumi Naka ; MD ; PhD^e ; O. Howard Frazier ; MD^f
• 关键词：27
• 刊名：The Journal of Thoracic and Cardiovascular Surgery
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：145
• 期：2
• 页码：548-554
• 全文大小：339 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Objectives

Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to recovery or to the next therapy, and improve the outcomes.

Methods

Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardiopulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was longer. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which included recovery at 30 days after device removal and bridge-to-other-therapy.

Results

Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m² (P?=?.0001); mean arterial pressure, 71.4 versus 83.1 mm Hg (P?=?.01); and pulmonary artery diastolic pressure, 28.0 versus 19.8 mm Hg (P?<?.0001). The pump provided an average of 4.0 ¡À 0.6 L/min of flow for an average duration of 3.7 ¡À 2.9 days (range, 1.7-12.6). The primary safety endpoint occurred in 2 patients (13 % ; 1 stroke and 1 death). For the primary efficacy endpoint, recovery of the native heart function was obtained in 93 % of the patients discharged, with bridge-to-other-therapy in 7 % . Survival to 30 days, 3 months, and 1 year was 94 % , 81 % , and 75 % , respectively.

Conclusions

The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.